All posts

You haven’t missed the boat on Sylogist, Echelon says

The stock has been on a tear since December, but there is still money to be made on Sylogist (Sylogist Stock Quote, Chart, News, Analysts, Financials TSX:SYZ), Echelon analyst Amr Ezzat says.

In a research update to clients April 14, Ezzat maintained his “Buy” rating but raised his price target on SYZ from $11.00 to $12.50.

The analyst explained the reasoning behind his increased confidence in SYZ.

“We hosted a series of in-person investor meetings with Sylogist last week,” he wrote. “The discussions during these sessions have further solidified our positive outlook on the Company, reinforcing our conviction in its strategic direction, market positioning, and the effectiveness of its leadership team in executing its growth strategy. This note highlights key themes from the roadshow, namely (1) the sustainability of the Company’s revitalized growth profile, (2) the Company’s evolving go-to-market and delivery model, and (3) the operating leverage going forward. We’re reiterating our Buy rating (Top Pick status), introducing 2026 estimates, and moving our PT to $12.50/shr from $11.00/shr.”

Ezzat thinks SYZ will generate EBITDA of $19.1-million on revenue of $73.1-million in fiscal 2024. He expects those numbers will improve to EBITDA of $25.0-million on a topline of $84.1-million the following year.

The analyst explained why he thinks the company’s revenue growth will not go away.

“The resurgence in growth is not a transient phenomenon but a well-orchestrated outcome of strategic decisions, particularly under the leadership of a revitalized management team and board. As discussed below, significant investments in sales and marketing, as well as research and development, have enabled Sylogist’s products to leapfrog those of its competitors and have laid a solid foundation for continued growth,” he added.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: syz
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

7 hours ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

8 hours ago

Is GOOGL still a buy?

Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]

1 day ago

NLH has 173% upside, Echelon says

Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]

1 day ago

Shopify upgraded to “Buy” at Citi

The stock has been flat since November, but Citi analyst Tyler Radke thinks there is now money to be made… [Read More]

1 day ago

Sabio has 400% upside, Eight Capital says

Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]

4 days ago